Puma Biotech (PBYI) Misses Q4 EPS by 3c

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.80), $0.03 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $53.65 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00